PubMed Health⌕ Search

Biomedical subjects

Stanley F Nelson

Publications and source records attributed to Stanley F Nelson.

39 records · Page 3Linked to original sources

A genomewide scan for loci involved in attention-deficit/hyperactivity disorder.

Attention deficit/hyperactivity disorder (ADHD) is a common heritable disorder with a childhood onset. Molecular genetic studies of ADHD have previously focused on examining the roles of specific candidate genes, primarily those involved in dopaminergic pathways. We have performed the first systematic genomewide linkage scan for loci influencing ADHD in 126 affected sib pairs, using a approximately 10-cM grid of microsatellite markers. Allele-sharing linkage methods enabled us to exclude any loci with a lambda(s) of > or =3 from 96% of the genome and those with a lambda(s) of > or =2.5 from 91%, indicating that there is unlikely to be a major gene involved in ADHD susceptibility in our sample. Under a strict diagnostic scheme we could exclude all screened regions of the X chromosome for a locus-specific lambda(s) of >/=2 in brother-brother pairs, demonstrating that the excess of affected males with ADHD is probably not attributable to a major X-linked effect. Qualitative trait maximum LOD score analyses pointed to a number of chromosomal sites that may contain genetic risk factors of moderate effect. None exceeded genomewide significance thresholds, but LOD scores were >1.5 for regions on 5p12, 10q26, 12q23, and 16p13. Quantitative-trait analysis of ADHD symptom counts implicated a region on 12p13 (maximum LOD 2.6) that also yielded a LOD >1 when qualitative methods were used. A survey of regions containing 36 genes that have been proposed as candidates for ADHD indicated that 29 of these genes, including DRD4 and DAT1, could be excluded for a lambda(s) of 2. Only three of the candidates-DRD5, 5HTT, and CALCYON-coincided with sites of positive linkage identified by our screen. Two of the regions highlighted in the present study, 2q24 and 16p13, coincided with the top linkage peaks reported by a recent genome-scan study of autistic sib pairs.

Alleles↗

Identification of genes required for immortalization in human papillomavirus-infected human oral keratinocytes.

The early stages of head and neck cancer are presumed to require a senes of genetic alterations that are not represented by a distinct clinical phenotype. Therefore, genes with altered expression in the preneoplasia may be useful for the early detection of this highly recurrent cancer. In this study, we immortalized normal human oral keratinocytes (NHOK) by retroviral-mediated infection of HPV 16 transforming oncogenes, E6 and E7 (HOK16E6E7). Using the Affymetrix gene chip (U95Av2), we identified 177 known genes and EST that were overexpressed at least 3-fold or above in the immortalized cells, while 133 were down-regulated compared to NHOK. Northern blot analysis showed elevated levels of p55CDC in the immortalized cells, while NHOK showed high basal expression of small proline rich protein (SPRR2). The altered expression of these genes maybe associated with cellular proliferation or differentiation and the early stages of oral carcinogenesis.

Blotting, Northern↗

Molecular analysis of glioblastoma: pathway profiling and its implications for patient therapy.

Technological advances in the ability to analyze patterns of gene expression and signal transduction pathway activation are improving our understanding of cancer. Previously unrecognized molecular subsets and pathway profiles that convey predictive and prognostic information about individual cancer patients are being identified. Patients with glioblastoma, the most common malignant primary brain tumor of adults, stand to benefit considerably from these advances. Recent data suggest that morphologically indistinguishable glioblastomas have distinct classes of causal oncogene activation, and that these subclasses may be targetable by oncogene/signaling pathway specific therapies. Oncogene/signaling pathway inhibitors show great promise for the treatment of patients with some types of cancer, but their clinical application for glioblastoma has been severely limited by an inability to determine which inhibitor is most likely to benefit a specific patient. Identifying biologically relevant molecular subsets of glioblastoma and detecting pathway profiles that can be used to guide patient therapy are likely to result in significant improvement in the survival of glioblastoma patients.

Animals↗